Asset Details
Do you wish to reserve the book?
Adrenomedullin Inhibits the Efficacy of Combined Immunotherapy and Targeted Therapy in Biliary Tract Cancer by Disrupting Endothelial Cell Functions
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Adrenomedullin Inhibits the Efficacy of Combined Immunotherapy and Targeted Therapy in Biliary Tract Cancer by Disrupting Endothelial Cell Functions
Do you wish to request the book?
Adrenomedullin Inhibits the Efficacy of Combined Immunotherapy and Targeted Therapy in Biliary Tract Cancer by Disrupting Endothelial Cell Functions
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Adrenomedullin Inhibits the Efficacy of Combined Immunotherapy and Targeted Therapy in Biliary Tract Cancer by Disrupting Endothelial Cell Functions
2025
Overview
ABSTRACT
The global incidence of biliary tract cancer (BTC) is on the rise, presenting a substantial healthcare challenge. The integration of immune checkpoint inhibitors (ICIs) with molecularly targeted therapies is emerging as a strategy to enhance immune responses. However, the efficacy and underlying mechanisms of these treatments in BTC are still largely unexplored. In this study, tissue samples from 19 BTC patients treated with camrelizumab and apatinib were analysed using the NanoString 289‐panel to identify key molecular biomarkers. Comparative analyses and subsequent experimental validations, including cell‐based assays and histopathological examinations, identified adrenomedullin (ADM) as a critical molecular marker associated with treatment efficacy and poor prognosis. ADM has been shown to promote BTC cell proliferation, migration and angiogenesis, primarily by interacting with vascular endothelial growth factor (VEGF) and increasing AKT phosphorylation. Furthermore, ADM disrupts endothelial cell barrier function via the calcitonin receptor‐like receptor (CRLR) and vascular endothelial (VE)‐cadherin signalling pathway. Preclinical inhibition of ADM or CRLR resulted in suppressed tumour growth. Additionally, elevated ADM expression was correlated with increased tumour‐infiltrating immune cells and higher immune checkpoint expression. These findings suggest that ADM plays a pivotal role in resistance to immunotherapy and anti‐angiogenic treatment in BTC, and thus, targeting ADM may offer a promising therapeutic approach to enhance treatment efficacy.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
/ Adrenomedullin - pharmacology
/ Aged
/ Animals
/ Antibodies, Monoclonal, Humanized - pharmacology
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Biliary Tract Neoplasms - drug therapy
/ Biliary Tract Neoplasms - immunology
/ Biliary Tract Neoplasms - metabolism
/ Biliary Tract Neoplasms - pathology
/ Biliary Tract Neoplasms - therapy
/ Calcitonin Receptor-Like Protein - metabolism
/ calcitonin receptor‐like receptor
/ Cancer
/ Cell Movement - drug effects
/ Cell Proliferation - drug effects
/ Cells
/ Endothelial Cells - drug effects
/ Endothelial Cells - metabolism
/ Endothelial Cells - pathology
/ Female
/ Genes
/ Humans
/ Immune checkpoint inhibitors
/ Male
/ Mice
/ Neovascularization, Pathologic
/ Original
/ Patients
/ Proteins
/ Signal Transduction - drug effects
/ Tumors
